HAVEN, Conn., Sept. 22,
2022 /PRNewswire/ -- Trevi Therapeutics, Inc.
(NASDAQ: TRVI), a clinical-stage biopharmaceutical company
developing an investigational therapy, Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in adults with
idiopathic pulmonary fibrosis (IPF) and the treatment of prurigo
nodularis (PN), today announced the pricing of its underwritten
public offering of [●] shares of its common stock at a public
offering price of $[●] per share, and, to certain investors in lieu
of common stock, pre-funded warrants to purchase [●] shares of
common stock at a price of $[●] per pre-funded warrant, for total
proceeds of [approximately] $[●] million, before deducting
underwriting discounts and commissions and expenses payable by
Trevi. The purchase price per share of each pre-funded warrant
represents the per share public offering price for the common
stock, minus the $[●] per share exercise price of such pre-funded
warrant. All of the shares and pre-funded warrants in the offering
are being sold by Trevi. In addition, Trevi has granted the
underwriters a 30-day option to purchase up to [●] additional
shares of its common stock at the public offering price, less
underwriting discounts and commissions. The offering is expected to
close on September [●], 2022, subject to satisfaction of customary
SVB Securities, Stifel and Oppenheimer & Co. are acting as
joint bookrunning managers for the offering. Needham &
Company is acting as lead manager for the offering and Aegis
Capital Corp. is acting as co-manager for the offering.
The shares and pre-funded warrants are being offered by Trevi
pursuant to a shelf registration statement that was filed with the
Securities and Exchange Commission ("SEC") on June 26, 2020 and declared effective by the SEC
on July 2, 2020. This offering is
being made only by means of a prospectus and prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC and may be obtained for free
by visiting the SEC's website at www.sec.gov. A final prospectus
supplement relating to the offering will be filed with the SEC.
When available, copies of the final prospectus supplement and the
accompanying prospectus may also be obtained from SVB Securities
LLC, Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109 by email at
email@example.com or by phone at (800) 808-7525, ext.
6105; Stifel, Nicolaus & Company, Incorporated, Attention:
Syndicate, One Montgomery Street,
Suite 3700, San Francisco, CA
94014, by telephone at 415-364-2720 or by email at
firstname.lastname@example.org; or Oppenheimer & Co. Inc., 85 Broad
Street, 26th Floor, New York, NY
10004, Attn: Syndicate Prospectus Department, telephone: (212)
667-8055 or by email at EquityProspectus@opco.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of the
investigational therapy Haduvio for the treatment of chronic cough
in adults with idiopathic pulmonary fibrosis and prurigo nodularis.
These conditions share a common pathophysiology that is mediated
through opioid receptors in the central and peripheral nervous
Founded in 2011, Trevi is headquartered in New Haven,
Statements contained in this press release regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties and
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to, statements about the anticipated
closing of the public offering, and other statements containing the
words "believes," "anticipates," "plans," "expects," and similar
expressions. Risks that contribute to the uncertain nature of the
forward-looking statements include: uncertainties related to market
conditions and whether the conditions for the closing of the public
offering will be satisfied as well as other risks and uncertainties
set forth in the "Risk Factors" section of the preliminary
prospectus supplement filed with the SEC on September [__], 2022,
in Trevi's quarterly report on Form 10-Q for the quarter ended
June 30, 2022 filed with the SEC, and
in any subsequent filings with the SEC. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Trevi undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made
except as required by law.
Trevi Therapeutics, Inc.
View original content to download
SOURCE Trevi Therapeutics, Inc.